ArticleCritical care explorations2026
The Tip of the Iceberg: Pathway Biology Must Anchor the Next Generation of Critical Care Trials.
Article in Critical care explorations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sepsis-associated acute lung injury: do inflammatory lipid mediators flood the lungs by activating pulmonary TRP channels?Intensive care medicine experimental · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heterogeneity of treatment effect has yielded decades of negative critical care trials. Syndromic diagnoses like sepsis and acute respiratory distress syndrome mask distinct molecular programs that respond differently to the same intervention, and single biomarkers lack the resolution to capture this complexity. Recent evidence now demonstrates that each step of the enrichment pipeline, from real-time bedside endotyping to prospective endotype-matched therapy, is clinically operational. However, current approaches rely on limited biomarker panels that capture only surface-level biology. Pathway biology, examining coordinated dysregulation of molecular networks rather than isolated analytes, offers the deeper resolution needed to match patients to targeted therapies. We propose a translational pipeline integrating multiomics, pathway analysis, machine learning, and point-of-care assays to advance critical care toward pathway-focused predictive enrichment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.